ACRS Aclaris Therapeutics, Inc.

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

Aclaris Therapeutics, Inc. (ACRS) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q1 2025 earnings press release filed as exhibit — refer to Exhibit 99.1 for actual financial results
• Filing explicitly excludes Item 2.02 disclosure from liability under Exchange Act Section 18

+1 more insights

Other Aclaris Therapeutics, Inc. 8-K Filings

8-K Mar 11, 2026

8-K Mar 10, 2026

Get deeper insights on Aclaris Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.